NRIX: Bull Flag detected on 14 Jul 2026

NRIX is forming a bull flag consolidation pattern at $22.71, sandwiched between key support at $21.23 and resistance at $24.88. The pattern quality scores are solid: structure 15.0/15, volume 11.2/12, and breakout 10.6/13, yielding an overall 75.8/98 score with a 73.21% win probability. Recent price action shows -5.5% decline in the last week after a strong 48% gain over one month, consistent with post-earnings flag formation.

On July 9, 2026—just five days ago—Nurix announced a transformative $2.3 billion global collaboration with Roche, including a $700 million upfront payment, to co-develop its lead asset bexobrutideg, a BTK degrader for malignant hematology, immunology, and neurology indications. This strategic win, combined with pro-forma cash of ~$1.14 billion, fundamentally de-risks the clinical and commercial pathway. The company reported a 92.9% objective response rate in one CLL patient cohort, validating the science. The timing of this blockbuster catalyst—announced just days before pattern formation—explains why the stock consolidated after the initial pop, a typical response after outsized single-catalyst moves.

A successful bull flag breakout would target $23.46 (conservative target), requiring a close above resistance at $24.88 with above-average volume—ideally 2.4M+ shares (matching the 20-day average of 2.44M, versus current 1.55M at 0.63x ratio). Invalidation occurs at support $21.23, where the flag's lower boundary breaks. The 73.21% win probability and strong structural/breakout scores suggest upside asymmetry if volume confirmation arrives on a breakout attempt.

The Health Care sector regime is bullish (+0.83), but the overall market is bearish (-0.26), creating cross-current pressure. RSI at 62.26 is moderately elevated but not overbought, and volatility is elevated at 68.1% over 20 days with a beta of 1.06—standard for biotech but amplifies swings. Critical near-term risk: the Phase 3 DAYBreak CLL-306 confirmatory trial dosing its first patient in mid-2026, meaning clinical trial results remain uncertain despite the Roche deal. Current volume is 37% below average, signaling weak conviction; breakout requires volume confirmation. Clinical trial setbacks, regulatory delays, or macro selloff in biotech would breach support quickly.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.